A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Prostate cancer incidence is increasing, especially in advanced stages, reversing previous declines and slowing mortality rate improvements. Racial disparities persist, with Black and Native American ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Following almost a decade of decline, prostate cancer incidence in the U.S. increased 3.0% per year between 2014 through 2021, according to a report published Sept. 2 in CA: A Cancer Journal for ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Cancer death rates in the United States have dropped 25 percent since the early 1990s, a new report reveals. The finding was drawn from the American Cancer Society’s latest cancer incidence and ...

Prostate cancer is the second leading cause of cancer deaths in men, according to the South Carolina Department of Public ...

Sept. 16 -- TUESDAY, Sept. 15 (HealthDay News) -- Older men diagnosed with prostate cancer who choose watchful waiting are doing better these days than in the era before screening with a test for ...